Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19103


Purpose:

This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.


Study summary:

OBJECTIVES: I. Determine the sensitivity of the sentinel lymph node in the determination of lymph node metastases, using preoperative or intraoperative lymphatic mapping, in patients with stage IB1 cervical cancer. II. Determine the false-negative predictive value of the sentinel lymph node in the determination of lymph node metastases in these patients. OUTLINE: This is a multicenter study. Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.


Criteria:

Inclusion Criteria: - Diagnosis of carcinoma of the cervix of 1 of the following cellular types: - Squamous cell carcinoma - Adenocarcinoma - Adenosquamous cell carcinoma - Stage IB1 disease (no greater than 4 cm) - No unequivocal evidence of metastases - Adequate surgical candidate - No known allergy to triphenylmethane compounds - No prior pelvic irradiation - No prior retroperitoneal surgery - More than 4 weeks since prior cold knife or loop electrosurgical excision procedure (LEEP) cone biopsy - Prior cone biopsy allowed provided current disease is stage IB1


NCT ID:

NCT00070317


Primary Contact:

Principal Investigator
Charles Levenback
Gynecologic Oncology Group


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19103
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.